Echinocandins in invasive candidiasis

John Simon, Hsin Yun Sun, Hoe Nam Leong, Marie Yvette C. Barez, Po Yen Huang, Deepak Talwar, Jen Hsien Wang, Melor Mansor, Bambang Wahjuprajitno, Atul Patel, Siriporn Wittayachanyapong, B. Shoib Mohd Sany, Sheng Fong Lin, George Dimopoulos

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


We summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managing IC. The echinocandins have demonstrated good activity against non-albicans infections and also azole-resistant strains, both preclinically and in recent clinical trials. As well as proving efficacious, echinocandins have a favourable safety profile and are well tolerated, including among inpatient subpopulations, such as transplant recipients and those with renal or hepatic dysfunction. In addition the echinocandins generally have minimal drug-drug interactions, unlike the oral azoles, which have multiple effects on cytochrome P450-mediated drug metabolism. Echinocandins are characterised by a good safety profile, few drug-drug interactions and good susceptibilities. With the increase in potentially azole-resistant non-albicans infections, echinocandins may become the first-line treatment of choice for many patients.

Original languageEnglish
Pages (from-to)601-609
Number of pages9
Issue number6
Publication statusPublished - Nov 2013


  • Candidaemia
  • Critically ill
  • Echinocandins


Dive into the research topics of 'Echinocandins in invasive candidiasis'. Together they form a unique fingerprint.

Cite this